Business
Rasna Therapeutics, Inc. Appoints Dr Alessandro Padova as Chairman
Rasna Therapeutics, Inc. Appoints Dr Alessandro Padova as Chairman.
About this update from Actavia Life Sciences, Inc.
[{"type":"text","content":"\n \n Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage \n biotechnology company focused on the development of cancer drugs, today \n announced the appointment of Dr Alessandro Padova as Chairman with \n immediate effect.\n \n \n “We are delighted to welcome Alessandro to the Rasna team and look \n forward to the positive contribution of his leadership, experience and \n successful international track record of progressing assets through \n clinical development,” commented Jim Tripp, CEO of Rasna.\n \n \n Dr Padova will continue to serve in his role as Chief Executive Officer \n of Ri.MED Foundation, a unique US-Italy public-private translational \n research enterprise. He has previously held senior executive, managerial \n and scientific roles in the pharmaceutical and biotechnology sector with \n several prestigious UK and Italian biotech companies including Peptide \n Therapeutics, Medivir UK, Astex Technology, C4T S.C.ar.l., Siena Biotech \n and IRBM Science Park, where he led and implemented business, management \n and R&D strategies.\n \n \n Dr Padova obtained a BSc in Chemistry from the University of Kent and a \n PhD in Synthetic Organic Chemistry in 1994 at Exeter University, \n followed by an industrial post-doctoral fellowship at Parke-Davis \n Neuroscience Research Centre in Cambridge, UK.\n \n \n ###\n \n \n About Rasna Therapeutics, Inc.\n \n \n Rasna Therapeutics, Inc. is a development stage biotechnology company \n focused primarily on the development of drug candidates for leukemia and \n lymphoma. Abnormal epigenetic modification is recognized to play an \n important role in the pathogenesis of acute myeloid leukemia (AML), \n leading to silencing of genes involved in tumor suppression and cellular \n reproduction. Rasna’s focus on inhibition of lysine specific \n demethylase-1 (LSD1), an enzyme involved in epigenetic control, \n represents a promising and novel approach towards AML. Rasna has \n developed novel irreversible and reversible LSD1 regulators that have \n shown appropriate effects on the LSD1 gene in-vitro and in \n IND-enabling pre-clinical studies.\n \n \n Rasna Therapeutics Forward-Looking Statements\n \n \n This press release contains “forward-looking statements” as that term is \n defined in the Private Securities Litigation Reform Act of 1995, \n re...